Cytokine release syndrome: how pharma is tackling a 21st century disease

Future of cancer treatment: what will therapy look like in 2034?

2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year

AI program finds multiple influenza drug targets

Poolbeg expands POLB 001 into oncology

Poolbeg influenza trial successfully completed

Poolbeg-led consortium awarded €2.3m to develop oral vaccine platform

AI program yields multiple novel RSV drug targets

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

OneThree Biotech completes build and optimization of AI model for RSV data